Biotech Analysts discuss AL Amyloidosis and the potential of NXC-201 (relevant companies IMMX, REGN, ABBV, AZ, JNJ, GSK (GSK)) on an Analyst/Industry conference call to be held on April 15.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMMX:
- Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201
- Immix Biopharma completes NEXICART-2 enrollment, onboards CMO Richard Graydon
- Immix Biopharma price target raised to $15 from $14 at Mizuho
- Immix Biopharma price target raised to $15 from $12 at H.C. Wainwright
- Immix Biopharma Amends ATM Offering to Raise Capital